Millendo Therapeutics Stock

MLND

US60040X1037

Biotechnology & Medical Research

Latest news: Millendo Therapeutics

23-05-10	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
22-12-29	Millendo Therapeutics, Inc. and Tempest Therapeutics, Inc. Enter into First Amendment to Loan and Security Agreement	CI
21-09-30	Millendo Therapeutics, Inc. Joins Nicholas Maestas as Vice President, Strategy and Finance and It's Principal Financial Officer	CI
21-06-25	Millendo Therapeutics, Inc.(NasdaqCM:MLND) dropped from NASDAQ Composite Index	CI
21-06-24	Tempest Therapeutics Inc. completed the acquisition of Millendo Therapeutics, Inc. in a reverse merger transaction for approximately $180 million.	CI
21-06-22	Millendo Therapeutics : , Tempest Therapeutics Investors Approve Merger Proposals	MT
21-05-13	Millendo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-03-29	Millendo Therapeutics, Inc., Tempest Therapeutics Inc. - M&A Call
21-03-29	Millendo Therapeutics : Tempest, Millendo Agree to Merge, Combined Company to List on NASDAQ	MT
21-03-29	Millendo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	CI
21-03-28	Tempest Therapeutics Inc. entered into a definitive agreement and plan of merger to acquire Millendo Therapeutics, Inc. in a reverse merger transaction.	CI
21-01-28	Millendo Therapeutics, Inc. Announces Executive Changes	CI
21-01-28	Millendo Therapeutics, Inc. Plans to Reduce Its Workforce with Majority of Reduction in Personnel Expects to Complete by April 15, 2021	CI

More news

Analysts' recommendations: Millendo Therapeutics

21-01-06	Millendo Therapeutics : Ladenburg Thalmann Downgrades Millendo Therapeutics to Neutral from Buy	MT
21-01-06	Millendo Therapeutics : SVB Leerink Downgrades Millendo Therapeutics to Market Perform From Outperform; Price Target is $2	MT
20-11-09	Millendo Therapeutics : Wedbush Adjusts Price Target for Millendo Therapeutics to $2 From $3, Maintains Neutral Rating	MT

More recommendations

Press Releases: Millendo Therapeutics

21-07-23	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-07-16	Tempest Therapeutics : BUSINESS (Form 8-K)	PU
21-07-16	TEMPEST THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-07-12	Tempest Therapeutics : to Participate in William Blair 2021 Biotech Focus Conference	AQ
21-07-12	TEMPEST THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ

More press releases

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MILLENDO THERAPEUTICS	-14.88%	+3.21%	-	-	303M
WUXI APPTEC CO., LTD.	-2.59%	-5.70%	+50.69%	+86.86%	70.61B
ARGENX SE	+3.23%	-10.67%	+6.27%	+53.48%	51.01B
LONZA GROUP AG	+1.56%	+1.17%	+8.49%	+32.39%	48.1B
IQVIA HOLDINGS INC.	+0.39%	+0.65%	+31.14%	+27.04%	42.78B
REVOLUTION MEDICINES, INC.	+0.87%	-8.17%	+293.37%	+643.87%	40.67B
BEONE MEDICINES AG	+1.24%	-1.01%	+10.74%	+94.55%	40.3B
CELLTRION, INC.	-2.13%	-1.64%	+8.63%	+46.88%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.46%	-1.28%	+42.23%	+14.70%	28.16B
BIONTECH SE	+5.32%	+0.06%	-5.00%	-12.60%	24.36B
Average	-0.74%	-2.66%	+49.62%	+109.68%	41.84B
Weighted average by Cap.	+0.55%	-2.94%	+51.35%	+114.49%

See all sector performances

Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.

Employees

Sector

Biotechnology & Medical Research

More about the company